CSWYY OTC
China Shineway Pharmaceutical Group Limited
1W: +13.1%
1M: +26.9%
3M: +11.6%
YTD: +11.6%
1Y: +11.6%
3Y: +26.6%
5Y: +20.1%
$21.49
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$963M
+3.3% ▲
5Y CAGR: +21.2%
Capital Expenditures
$140M
+2.9% ▲
5Y CAGR: +9.6%
Free Cash Flow
$823M
+4.4% ▲
5Y CAGR: +24.1%
Dividends Paid
$408M
-28.6% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$251M
-70.9% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $295M | $557M | $723M | $1.2B | $1.1B |
| Depreciation & Amort. | $208M | $182M | $186M | $177M | $69M |
| Stock-Based Comp. | $131K | $34K | $0 | $0 | $0 |
| Change in Working Capital | -$105M | -$207M | -$228M | -$94M | $222M |
| Other Non-Cash Items | $135M | -$36M | $429M | -$391M | -$473M |
| Operating Cash Flow | $639M | $703M | $1.1B | $933M | $963M |
| — Investing Activities — | |||||
| Capital Expenditures | -$66M | -$94M | -$129M | -$144M | -$140M |
| Acquisitions (Net) | -$137M | $9M | $920K | $0 | $2M |
| Investment Purchases | -$2.5B | -$370M | -$320M | -$520M | -$845M |
| Investment Sales | $2.5B | $379M | $307M | $531M | $528M |
| Other Investing | -$147M | $470M | $97M | $84M | $183M |
| Investing Cash Flow | -$306M | $395M | -$45M | -$50M | -$272M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$29M | -$369M | $0 | $300M | $30M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$241M | -$453M | -$242M | -$317M | -$408M |
| Other Financing | -$23M | -$10M | -$8M | -$9M | -$15M |
| Financing Cash Flow | -$330M | -$829M | -$250M | -$27M | -$392M |
| Net Change in Cash | -$3M | $263M | $821M | $863M | $251M |
| Cash End of Period | $3.9B | $4.2B | $5.0B | $5.9B | $6.1B |
| Free Cash Flow | $573M | $610M | $980M | $788M | $823M |